TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19385031

Group type: EXPERIMENTAL
Intervention: Three-day energy restrictive diet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Three-day energy balanced diet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Breakfast preload followed by lunch request
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Energy restriction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ghrelin concentrations
Number of subjects: 20
Study: 16912022

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 60
Study: 15001607

Group type: EXPERIMENTAL
Intervention: Low-dose testosterone enanthate (1 mg/kg) and letrozole (2.5 mg orally once a day for 0-12 months)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 14
Study: 11396248

Group type: EXPERIMENTAL
Intervention: Standard heparin (SH) 2 x 7500 U s.c.
Number of subjects: 166

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH) Dalteparin 1 x 5000 anti-Xa U s.c. once daily.
Number of subjects: 166
Study: 9404791

Group type: EXPERIMENTAL
Intervention: Patching of CEDs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-patching of CEDs
Number of subjects: 0
Study: 8495017

Group type: EXPERIMENTAL
Intervention: Health education strategy performed by nursing personnel at the patient's home
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health education strategy performed by health professionals by telephone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health education strategy performed by the physician in his surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no health education strategy)
Number of subjects: 0
Study: 6403808

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard nutritional support
Number of subjects: 10
Study: 30633660

Group type: EXPERIMENTAL
Intervention: Glycine (0.8 g/kg weekly for 12 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (matching to glycine, provided in bottles with mixed in solution)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glycine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28981832

Group type: EXPERIMENTAL
Intervention: Cognitive composite score
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Verbal learning subscale scores
Number of subjects: 1045
Study: 27077672

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combination of rosiglitazone and rhGH
Number of subjects: 72

Group type: COMPARATOR
Intervention: rhGH
Number of subjects: 72
Study: 25051839

Group type: EXPERIMENTAL
Intervention: Silibinin combined with Ruangan pills
Number of subjects: 200

Group type: COMPARATOR
Intervention: Silibinin alone
Number of subjects: 200
Study: 22270273

Group type: EXPERIMENTAL
Intervention: Lubricating gel (0.3 mL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Water (3 mL)
Number of subjects: 120
Study: 19241078

Group type: EXPERIMENTAL
Intervention: Docetaxel plus 500 mg zosuquidar.3HCl (DZ)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Docetaxel plus placebo (DP)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Docetaxel plus zosuquidar.3HCl (DZ)
Number of subjects: 170
Study: 21352110

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT) for 12 months
Number of subjects: 128

Group type: COMPARATOR
Intervention: Supportive Counselling (SC) for 12 months
Number of subjects: 128
Study: 16970116

Group type: EXPERIMENTAL
Intervention: MLCu 375
Number of subjects: 157

Group type: COMPARATOR
Intervention: TCu 380A
Number of subjects: 157
Study: 15187819

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (2 g orally in effervescent tablets)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (oral in effervescent tablets)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Hypercholesterolaemic patients (Group A and B combined)
Number of subjects: 46
Study: 10789607

Group type: EXPERIMENTAL
Intervention: Patient comprehension of the trial
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Recollection of explanation duration
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Opportunity for discussion at consent
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Patient consent motivation
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Perceived treatment improvement
Number of subjects: 150
Study: 8902254

Group type: EXPERIMENTAL
Intervention: Magnesium (10 mmol twice-daily)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 69
Study: 1862029

Group type: EXPERIMENTAL
Intervention: 10% sulfur in cold cream
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 10% sulfur and 1% salicylic acid in pork fat
Number of subjects: 58
Study: 6140811

Group type: EXPERIMENTAL
Intervention: Oral propranolol (40 mg X 2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31795961

Group type: EXPERIMENTAL
Intervention: Midwives providing physical activity advice and guidance
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Opportunities proposed by midwives to facilitate physical activity engagement
Number of subjects: 10
Study: 26953228

Group type: EXPERIMENTAL
Intervention: OA&CHX rinse group
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: COMBI group (OHI + PP + OA&CHX)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control I & II, OHI, PP
Number of subjects: 267
Study: 26139054

Group type: EXPERIMENTAL
Intervention: Everolimus-Eluting Stents (EES)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Drug-Eluting Balloons (DEB)
Number of subjects: 309
Study: 24018369

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (12 sessions over 6 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional physiotherapy (same amount as experimental group)
Number of subjects: 16
Study: 21315641

Group type: EXPERIMENTAL
Intervention: Intervention group (letter and phone call)
Number of subjects: 828

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 828
Study: 19700442

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg i.v.
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg i.v.
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo (normal saline i.v.)
Number of subjects: 162
Study: 16234833

Group type: EXPERIMENTAL
Intervention: Supplemented with high-energy, nutrient dense food from 4 to 7 months of age, twice daily under supervision of field workers.
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Supplemented infants
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control infants
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Supplemented infants' mothers
Number of subjects: 134
Study: 15598388

Group type: EXPERIMENTAL
Intervention: Preoperative analgesia with Tramadol and Ondansetron in group B
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Preoperative analgesia with Midazolam, Tramadol, and Ondansetron in group C
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group A (no preoperative analgesia)
Number of subjects: 210
Study: 10755105

Group type: EXPERIMENTAL
Intervention: Dorzolamide 2% twice daily added to timolol maleate 0.5% twice daily
Number of subjects: 62

Group type: COMPARATOR
Intervention: Timolol maleate 0.5% twice daily (monotherapy)
Number of subjects: 62
Study: 9015696

Group type: EXPERIMENTAL
Intervention: Ritodrin treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Indomethacin treatment (Control)
Number of subjects: 25
Study: 8224310

Group type: EXPERIMENTAL
Intervention: Antibiotic ointment and mydriatic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibiotic ointment, mydriatic and double eye pad with bandage
Number of subjects: 0
Study: 4028870

Group type: EXPERIMENTAL
Intervention: 2.0 g ceftriaxone i.v.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.5 g ceftriaxone i.v.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.5 g ceftriaxone s.c.
Number of subjects: 10

Group type: COMPARATOR
Intervention: 2 g ceftriaxone i.v.
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.5 g ceftriaxone s.c. vs 0.5 g ceftriaxone i.v.
Number of subjects: 10
Study: 31470635

Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients (FM)
Number of subjects: 67
Study: 29788156

Group type: EXPERIMENTAL
Intervention: Dual therapy with atazanavir/ritonavir plus lamivudine
Number of subjects: 139

Group type: COMPARATOR
Intervention: Triple therapy with atazanavir/ritonavir plus two NRTIs
Number of subjects: 139
Study: 27585726

Group type: EXPERIMENTAL
Intervention: Virtual gastric band (VGB) hypnotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Relaxation hypnotherapy
Number of subjects: 30
Study: 25362680

Group type: EXPERIMENTAL
Intervention: Multimodal resilience training program including a 2-day educational workshop, written exposure sessions, event-triggered counseling sessions, mindfulness-based stress reduction exercises, and a protocolized aerobic exercise regimen.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 0
Study: 23086971

Group type: EXPERIMENTAL
Intervention: Atenolol (25 mg twice daily)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ivabradine (5 mg twice daily)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (1 tablet twice daily)
Number of subjects: 66
Study: 20735342

Group type: EXPERIMENTAL
Intervention: Music Therapy (MT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard Care (Control)
Number of subjects: 20
Study: 18846455

Group type: EXPERIMENTAL
Intervention: 60 ml of 300 mg I/ml contrast material (CM) in group A
Number of subjects: 58

Group type: COMPARATOR
Intervention: 40 ml of 370 mg I/ml contrast material (CM) in group B
Number of subjects: 58
Study: 16097363

Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg/day for 16 weeks)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Felodipine (5 mg/day for 16 weeks)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 11374114

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group B
Number of subjects: 30
Study: 9829378

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody B72.3 (Group A)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody FO23C5 (Group B)
Number of subjects: 64
Study: 7977903

Group type: EXPERIMENTAL
Intervention: Relational processing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Item-specific processing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intentional learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forced guessing in cued recall tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard cued recall tests
Number of subjects: 0
Study: 2723939

Group type: EXPERIMENTAL
Intervention: Tannin-rich carob pod powder (40% tannins, 1.5 g/kg/day, max 15 g)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Tannin-rich carob pod powder
Number of subjects: 41
Study: 1237822

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg a day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30922318

Group type: EXPERIMENTAL
Intervention: Free, single-purpose voucher approach
Number of subjects: 1276

Group type: COMPARATOR
Intervention: Control district (Bhakkar)
Number of subjects: 1276
Study: 28549903

Group type: EXPERIMENTAL
Intervention: Patellar strap
Number of subjects: 24

Group type: COMPARATOR
Intervention: No patellar strap (control condition)
Number of subjects: 24
Study: 25494389

Group type: EXPERIMENTAL
Intervention: AX-continuous performance test (AX-CPT; mental fatigue)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Emotionally neutral documentaries (control)
Number of subjects: 10
Study: 23459407

Group type: EXPERIMENTAL
Intervention: Losartan/HCTZ combination regimen
Number of subjects: 95

Group type: COMPARATOR
Intervention: High-dose losartan regimen
Number of subjects: 95
Study: 21562253

Group type: EXPERIMENTAL
Intervention: IVIg (Gamunex®, Talecris Biotherapeutics) 1 g/kg/day for 2 consecutive days
Number of subjects: 84

Group type: COMPARATOR
Intervention: PLEX (Caridian Spectra) 1.0 plasma volume exchanges for 5 exchanges
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both IVIg and PLEX
Number of subjects: 84
Study: 19080094

Group type: EXPERIMENTAL
Intervention: Nasal administration of fentanyl 0.5 microg/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intravenous injection of fentanyl 0.5 microg/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control Group B (sodium chloride)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 16571956

Group type: EXPERIMENTAL
Intervention: Vasopressor infusion right after SAB (n = 20)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Colloid prehydration until LF/HF decreased below 2.5 (n = 20)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group with low baseline LF/HF (n = 17)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group with high baseline LF/HF (n = 23)
Number of subjects: 80
Study: 12771390

Group type: EXPERIMENTAL
Intervention: Exposure to sulphuric acid mists
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Exposure to sulphuric acid concentrations higher than 200 micro g/m(3)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Exposed subjects
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (unexposed subjects)
Number of subjects: 52
Study: 10999865

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody prophylaxis
Number of subjects: 656

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Prophylaxis
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: High risk infants
Number of subjects: 656
Study: 8784067

Group type: EXPERIMENTAL
Intervention: methimazole, propranolol and cholestyramine for 4 weeks (group I)
Number of subjects: 30

Group type: COMPARATOR
Intervention: methimazole and propranolol for 4 weeks (group II)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: methimazole, propranolol, and cholestyramine for 2 weeks, followed by 2 weeks of methimazole and propranolol (group III)
Number of subjects: 30
Study: 1538151

Group type: EXPERIMENTAL
Intervention: Acyclovir (30 mg/kg/day at 8‐h intervals)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Vidarabine (10 mg/kg/day as a continuous 12‐h infusion for 7 days)
Number of subjects: 73
Study: 6468546

Group type: EXPERIMENTAL
Intervention: Vanillin
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Lactose
Number of subjects: 1

Group type: COMPARATOR
Intervention: Cellulose (recommended as a placebo)
Number of subjects: 1
Study: 29721693

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (monthly nutritional guidelines for 9 months)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study: 27496512

Group type: EXPERIMENTAL
Intervention: Intervention (rural sanitation programme)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study: 25542291

Group type: EXPERIMENTAL
Intervention: Hypertensive group (systolic arterial blood pressure maintained with phenylephrine infusion 20%‐30% over baseline)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (systolic arterial blood pressure maintained 20%‐30% below baseline)
Number of subjects: 50
Study: 23733761

Group type: EXPERIMENTAL
Intervention: Cisplatin plus cetuximab
Number of subjects: 173

Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 173
Study: 20464423

Group type: EXPERIMENTAL
Intervention: Minimally Invasive Esophagectomy (MIE)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Open Esophagectomy (OE)
Number of subjects: 62
Study: 18264935

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 16868545

Group type: EXPERIMENTAL
Intervention: Gemcitabine administered twice-weekly (40 mg/m²) for 5 weeks concurrent with upper abdominal radiation (50.4 Gy in 5(1/2) weeks) followed by weekly gemcitabine (1000 mg/m²) for two cycles (3 weeks treatment, 1 week off).
Number of subjects: 46
Study: 12788887

Group type: EXPERIMENTAL
Intervention: Intralipid infusion (24 hours)
Number of subjects: 20
Study: 10456487

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 50 mg per day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg per day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Tacrine 40 mg (first study period)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tacrine 20 mg (second study period)
Number of subjects: 18
Study: 8542164

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (2 x 100 micrograms, four times per day for 7 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (200 micrograms pretreatment)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (7 days treatment)
Number of subjects: 10
Study: 1985165

Group type: EXPERIMENTAL
Intervention: High-dose chemoradiotherapy (HD CT/RT) with melphalan 60 mg/m2/d for three doses and total body irradiation (TBI) of either 1.5 Gy (n = 27) or 2.0 Gy (n = 54) twice daily for six doses; 23 patients received additional irradiation of 1.2 Gy twice daily for 10 doses to persisting disease sites; 74 received autologous marrow, 7 allogeneic marrow.
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group not specified; all patients received HD CT/RT.
Number of subjects: 101
Study: 6342362

Group type: EXPERIMENTAL
Intervention: Vitamin E (800 IU/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3878301

Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline infusion (180 mg theophylline)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Choline theophyllinate administered rectally (400 mg theophylline)
Number of subjects: 21
Study: 28749253

Group type: EXPERIMENTAL
Intervention: Daily vulvar Visnadine spray
Number of subjects: 38

Group type: COMPARATOR
Intervention: On-demand vulvar Visnadine spray
Number of subjects: 38
Study: 27566219

Group type: COMPARATOR
Intervention: Iron sulfate, 600mg orally daily for 4 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Iron sulfate, 600mg orally daily for 4 weeks + rHuEPO, 4000 units subcutaneously, three times a week for 4 weeks
Number of subjects: 100
Study: 25172965

Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg twice daily for patients ≥70 kg or 0.5 mg once daily for patients <70 kg)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 360
Study: 22448718

Group type: EXPERIMENTAL
Intervention: Intravenous oxycodone (1 mg i.v. boluses, up to 5 mg cumulative dose)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (newborns after uncomplicated deliveries with no systemic opioids)
Number of subjects: 15
Study: 20722848

Group type: EXPERIMENTAL
Intervention: Web-based instruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paper-based instruction
Number of subjects: 0
Study: 18443983

Group type: EXPERIMENTAL
Intervention: complete intervention
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: partial intervention
Number of subjects: 323

Group type: COMPARATOR
Intervention: non‐treatment
Number of subjects: 323
Study: 16153270

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP) by unstable angina
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no angina)
Number of subjects: 19
Study: 14565797

Group type: EXPERIMENTAL
Intervention: Estradiol 2 mg
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 10378561

Group type: EXPERIMENTAL
Intervention: Antiseptic-impregnated catheter (AIC)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Nonimpregnated catheter (NIC)
Number of subjects: 101
Study: 9032584

Group type: EXPERIMENTAL
Intervention: One-week triple antimicrobial therapy (bismuth, tinidazole, amoxicillin)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Four-week triple antimicrobial therapy (bismuth, tinidazole, amoxicillin)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: One-week triple antimicrobial therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Four-week triple antimicrobial therapy
Number of subjects: 56
Study: 1648026

Group type: EXPERIMENTAL
Intervention: Intravenous atrial natriuretic peptide (6 pmol/min/kg for 90 minutes)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 6
Study: 6347755

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg three times a day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Paracetamol (1 g three times a day)
Number of subjects: 31
Study: 30758110

Group type: EXPERIMENTAL
Intervention: Biodegradable osteosynthesis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Titanium osteosynthesis
Number of subjects: 40
Study: 27492145

Group type: EXPERIMENTAL
Intervention: Kangaroo ward care (KWC)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Intermediate intensive care (IIC)
Number of subjects: 62
Study: 25377297

Group type: EXPERIMENTAL
Intervention: Urinary Continence Physiotherapy Programme (n=27)
Number of subjects: 55
Study: 23261418

Group type: EXPERIMENTAL
Intervention: High access cost condition with an interruption lag
Number of subjects: 0

Group type: COMPARATOR
Intervention: No lag control condition
Number of subjects: 0
Study: 21689448

Group type: EXPERIMENTAL
Intervention: 100,000 IU vitamin D2
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D2
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 20001457

Group type: EXPERIMENTAL
Intervention: Spironolactone (SPI)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Thiazide diuretic (TCTZ)
Number of subjects: 64
Study: 16758042

Group type: EXPERIMENTAL
Intervention: Erythropoietin (3 doses of 400 IU/kg per week for 6 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no treatment aside from conventional medications)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60